Werewolf Therapeutics, Inc. 8K

Werewolf Therapeutics reported Q4 and full year 2025 results and began a strategic alternatives review, engaging Piper Sandler to explore potential M&A and other transactions to maximize stockholder value.

Werewolf Therapeutics, Inc. announced its fourth quarter and full year 2025 financial results and disclosed that it has initiated a formal process to explore strategic alternatives to maximize stockholder value, which may include a sale of the company, a merger or business combination, asset sales, licensing or collaboration arrangements, or other strategic transactions. The company has engaged Piper Sandler & Co. as its exclusive financial advisor for this review, emphasized that there is no defined timeline or assurance that any transaction will result, and stated that it does not intend to provide further updates until a specific action is approved or further disclosure is deemed appropriate. Financially, Werewolf reported a year-end 2025 cash and cash equivalents balance of $57.1 million, expects this to fund operations into the fourth quarter of 2026, and reported reduced research and development and general and administrative expenses year-over-year, with a 2025 net loss of $60.8 million versus $70.5 million in 2024.

Filing Facts

CIK

1785530

Ticker

-

Form

8K

Source Type

sec

Accession

0001785530-26-000005

Alert Tier

8